Stoke Therapeutics Inc.
Organization details
- Legal name
- Stoke Therapeutics Inc.
- Former names
- ASOthera Pharmaceuticals, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Bedford
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- STOK
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001623526
- EIN
- 47-1144582
Board of directors
-
Adrian R. Krainer · DirectorSince 2023
-
Alexander Cumbo · DirectorSince 2026
-
Arthur A. Levin · DirectorSince 2023
-
Arthur Tzianabos · Director · Interim Executive ChairSince 2023
-
Clare Kahn · DirectorSince 2026
-
Edward M. Kaye M.D. · Director · CEOSince 2023
-
Garry E. Menzel · DirectorSince 2023
-
Ian F. Smith · Director · Chief Executive OfficerSince 2023
-
Jennifer Burstein · DirectorSince 2023
-
Julie Smith · DirectorSince 2023
-
Seth Loring Harrison · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
73.0%
-
87.0%
Board connections
7 of this board's directors also sit on 9 other boards. 9 are in the same sector.
-
Solid Biosciences Inc. Same sectorvia Alexander Cumbo, Clare Kahn and Ian F. Smith
-
Black Diamond Therapeutics Inc. Same sectorvia Garry E. Menzel
-
Climb Bio Inc. Same sectorvia Alexander Cumbo
-
Cytokinetics Incorporated Same sectorvia Edward M. Kaye M.D.
-
Exelixis Inc. Same sectorvia Julie Smith
-
Foghorn Therapeutics Inc. Same sectorvia Ian F. Smith
-
Odyssey Therapeutics Inc. Same sectorvia Ian F. Smith
-
Q32 Bio Inc. Same sectorvia Arthur Tzianabos
-
Vor Biopharma Inc. Same sectorvia Alexander Cumbo
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $8,975,300
- 81 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 2, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −6,995 | $26.38 | $184,513 |
| Nov 2, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −200 | $26.99 | $5,398 |
| Oct 2, 2026 | Allan Jonathan Officer (GENERAL COUNSEL & CORP SEC) | Open-market sale | −627 | $26.33 | $16,509 |
| Oct 1, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −1,051 | $26.16 | $27,494 |
| Sep 1, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −3,945 | $30.51 | $120,362 |
| Sep 1, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −1,600 | $31.06 | $49,696 |
| Aug 18, 2026 | Allan Jonathan Officer (GENERAL COUNSEL & CORP SEC) | Open-market sale | −2,716 | $32.01 | $86,939 |
| Aug 18, 2026 | Edward M. Kaye M.D. Director | Open-market sale | −11,930 | $32.01 | $381,879 |
| Aug 18, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −4,525 | $32.01 | $144,845 |
| Aug 18, 2026 | Allan Jonathan Officer (GENERAL COUNSEL & CORP SEC) | Open-market sale | −145 | $32.47 | $4,708 |
| Aug 18, 2026 | Edward M. Kaye M.D. Director | Open-market sale | −637 | $32.47 | $20,683 |
| Aug 18, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −242 | $32.47 | $7,858 |
| Aug 14, 2026 | Allan Jonathan Officer (GENERAL COUNSEL & CORP SEC) | Option exercise | +6,000 | — | — |
| Aug 14, 2026 | Edward M. Kaye M.D. Director | Option exercise | +26,250 | — | — |
| Aug 14, 2026 | Ticho Barry Officer (CHIEF MEDICAL OFFICER) | Option exercise | +10,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Stoke Therapeutics Inc.
Who is the CEO of Stoke Therapeutics Inc.?
Edward M. Kaye M.D. is Stoke Therapeutics Inc.'s CEO.
How many directors are on Stoke Therapeutics Inc.'s board?
Stoke Therapeutics Inc.'s board has 11 directors: Adrian R. Krainer, Alexander Cumbo, Arthur A. Levin, Arthur Tzianabos, Clare Kahn, Edward M. Kaye M.D., Garry E. Menzel, Ian F. Smith, Jennifer Burstein, Julie Smith and 1 other.
Are Stoke Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Stoke Therapeutics Inc. insiders made no open-market purchases and sold $9.0 million of shares in 81 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="stoke-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.